Haemonetics Corporation $HAE Shares Sold by Confluence Investment Management LLC

Confluence Investment Management LLC trimmed its holdings in shares of Haemonetics Corporation (NYSE:HAE) by 23.2% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 28,687 shares of the medical instruments supplier’s stock after selling 8,645 shares during the period. Confluence Investment Management LLC owned approximately 0.06% of Haemonetics worth $2,299,000 at the end of the most recent reporting period.

Several other institutional investors have also bought and sold shares of HAE. AQR Capital Management LLC grew its position in Haemonetics by 372.8% in the 3rd quarter. AQR Capital Management LLC now owns 2,128,878 shares of the medical instruments supplier’s stock valued at $102,814,000 after buying an additional 1,678,630 shares in the last quarter. River Road Asset Management LLC boosted its holdings in shares of Haemonetics by 18.7% in the second quarter. River Road Asset Management LLC now owns 1,655,676 shares of the medical instruments supplier’s stock valued at $122,586,000 after acquiring an additional 260,624 shares in the last quarter. Geode Capital Management LLC increased its stake in shares of Haemonetics by 1.9% during the second quarter. Geode Capital Management LLC now owns 1,244,624 shares of the medical instruments supplier’s stock valued at $92,873,000 after acquiring an additional 23,257 shares during the period. Dimensional Fund Advisors LP raised its holdings in Haemonetics by 2.5% during the third quarter. Dimensional Fund Advisors LP now owns 1,099,519 shares of the medical instruments supplier’s stock worth $53,587,000 after purchasing an additional 26,763 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC raised its holdings in Haemonetics by 11.7% during the third quarter. Allspring Global Investments Holdings LLC now owns 1,060,790 shares of the medical instruments supplier’s stock worth $51,777,000 after purchasing an additional 111,307 shares in the last quarter. Institutional investors and hedge funds own 99.67% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on HAE. CJS Securities upgraded Haemonetics to a “strong-buy” rating in a research report on Thursday, December 11th. Weiss Ratings reiterated a “hold (c)” rating on shares of Haemonetics in a research report on Monday, December 29th. BTIG Research reissued a “buy” rating and issued a $88.00 price target on shares of Haemonetics in a report on Friday, February 6th. Robert W. Baird set a $81.00 price objective on shares of Haemonetics in a research report on Friday, February 6th. Finally, JPMorgan Chase & Co. lifted their price objective on shares of Haemonetics from $62.00 to $74.00 and gave the stock a “neutral” rating in a research note on Friday, December 12th. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $83.89.

Haemonetics Stock Down 0.5%

Shares of Haemonetics stock opened at $58.58 on Friday. Haemonetics Corporation has a 12-month low of $47.31 and a 12-month high of $87.32. The firm has a market capitalization of $2.72 billion, a PE ratio of 16.14, a price-to-earnings-growth ratio of 1.23 and a beta of 0.28. The company has a quick ratio of 1.15, a current ratio of 1.75 and a debt-to-equity ratio of 1.01. The stock’s fifty day moving average is $64.33 and its 200-day moving average is $64.82.

Haemonetics (NYSE:HAE) last released its quarterly earnings results on Thursday, February 5th. The medical instruments supplier reported $1.31 earnings per share for the quarter, beating analysts’ consensus estimates of $1.27 by $0.04. The business had revenue of $338.97 million during the quarter, compared to analyst estimates of $331.90 million. Haemonetics had a return on equity of 27.32% and a net margin of 13.31%.Haemonetics’s revenue for the quarter was down 2.7% on a year-over-year basis. During the same quarter last year, the company posted $1.19 EPS. Haemonetics has set its FY 2026 guidance at 4.900-5.000 EPS. Equities analysts anticipate that Haemonetics Corporation will post 4.55 earnings per share for the current year.

Haemonetics Profile

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.